TRIB3 and cancer: Although long-term AZD9291 treatment reduced TRIB3 and EGFR expression, it upregulated the expression and phosphorylation of STAT3, STAT5, and ERK1/2 (Supplementary Fig. 7d), suggesting the compensatory activation of other oncogenic pathways and induction of cancer stemness.